MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.040
-0.163
-3.87%
Closed 16:00 02/14 EST
OPEN
4.010
PREV CLOSE
4.203
HIGH
4.125
LOW
3.900
VOLUME
9.66K
TURNOVER
--
52 WEEK HIGH
9.74
52 WEEK LOW
2.240
MARKET CAP
25.12M
P/E (TTM)
-3.2468
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KZIA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

KZIA News

  • Edison issues ADR update on Kazia Therapeutics (KZIA)
  • ACCESSWIRE.01/13 12:55
  • SBGL, OLLI among premarket gainers
  • Seeking Alpha - Article.12/11/2019 14:11
  • Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
  • PR Newswire.12/11/2019 00:41
  • Edison issues ADR outlook on Kazia Therapeutics (KZIA)
  • ACCESSWIRE.12/02/2019 13:45

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About KZIA

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
More

Webull offers Kazia Therapeutics Ltd (ADR) (KZIA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.